Regulatory and logistical issues influencing access to antineoplastic and supportive care medications for children with cancer in developing countries
Article first published online: 19 APR 2014
© 2014 Wiley Periodicals, Inc.
Pediatric Blood & Cancer
Volume 61, Issue 8, pages 1513–1517, August 2014
How to Cite
Wiernikowski, J. T., MacLeod, S. and for The Working Group on Essential Medicines of the Pediatric Oncology in Developing Countries committee of SIOP (2014), Regulatory and logistical issues influencing access to antineoplastic and supportive care medications for children with cancer in developing countries. Pediatr. Blood Cancer, 61: 1513–1517. doi: 10.1002/pbc.25049
Working group members: Barr R, Casanova M, Denburg A, Frazier L, Grynszpancholc E, Kienesberger A, MacLeod S, McGoldrick D, Petrilli S, Rousseau R, Weerasuriya K, and Wiernikowski J.
- Issue published online: 10 JUN 2014
- Article first published online: 19 APR 2014
- Manuscript Accepted: 7 MAR 2014
- Manuscript Received: 13 JAN 2014
- The Office of International Affairs, National Cancer Institute, Bethesda, MD, USA
- Kids Care Cancer, Edmonton, Canada
- Pediatric Oncology Group of Ontario, Toronto, Canada
- Roche Pharmaceuticals, Lausanne, Switzeraland
- St Baldrick's Foundation, Monrovia, USA
- cancer pharmacology;
- drug access;
- low/middle income countries;
Globally there are numerous impediments, both logistical, regulatory and more recently global drug shortages, hindering pediatric access to therapeutic drugs of all types. Efforts to reduce barriers are ongoing and are especially important in low and middle income countries and for children requiring treatment of conditions such as those encountered in pediatric oncology characterized by the risk of life threatening treatment failures. Progress has been made through the efforts of the World Health Organization and regulators in the US and Europe to encourage the development of therapeutic agents for use in pediatrics and measures taken have fostered the availability of stronger pediatric data to guide therapeutic decisions. Nonetheless, pharmaceuticals remain a global commodity, subject to regulation by the World Trade Organization and this has often had detrimental effects in low and middle income countries. This article emphasizes the need for closer international collaboration to address the barriers currently impeding access to antineoplastic and supportive care medicines for children. Pediatr Blood Cancer 2014; 61:1513–1517. © 2014 Wiley Periodicals, Inc.